Griffin Securities Starts EpiCept Corp. (EPCT) at Buy, Pipeline Looks Strong
Tweet
Share
E-mailGet Alerts EPCT Hot Sheet
Price: $0.08 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Join SI Premium – FREE
Griffin Securities initiates coverage on shares of EpiCept Corp. (NASDAQ: EPCT) with a Buy rating and $2.50 price target.
The company is currently doing a good job proving its capabilities in the vascular disrupting agents market as its Azixa is showing strong results in the Myrexis-sponsored clinical trials and the NCI has chosen Crolibulin for a clinical study.
Phase two trials of AmiKet have provided researchers with knowledgeable proof-of-concept data that is currently being used to find the right partner for future clinical development. EPCT is forecasting commercialization of the drug in 2015 and plans to begin pivotal trials as soon as next year.
2015 is also when Ceplene is expected to make is commercial launch in the U.S.. Later this year a Phase IV study is expected to be conducted which is looking to find interim data on the therapies efficacy against minimal residual disease and prognostic biomarkers. The firm notes, "The data should help finalize a pivotal trial design with a Special Protocol Assessment with the FDA."
The firm is currently estimating a loss of $0.23 in earnings for fiscal 2011.
For more ratings news on EpiCept Corp. click here and for the rating history of EpiCept Corp. click here.
Shares of EpiCept Corp. closed at $0.51 yesterday.
The company is currently doing a good job proving its capabilities in the vascular disrupting agents market as its Azixa is showing strong results in the Myrexis-sponsored clinical trials and the NCI has chosen Crolibulin for a clinical study.
Phase two trials of AmiKet have provided researchers with knowledgeable proof-of-concept data that is currently being used to find the right partner for future clinical development. EPCT is forecasting commercialization of the drug in 2015 and plans to begin pivotal trials as soon as next year.
2015 is also when Ceplene is expected to make is commercial launch in the U.S.. Later this year a Phase IV study is expected to be conducted which is looking to find interim data on the therapies efficacy against minimal residual disease and prognostic biomarkers. The firm notes, "The data should help finalize a pivotal trial design with a Special Protocol Assessment with the FDA."
The firm is currently estimating a loss of $0.23 in earnings for fiscal 2011.
For more ratings news on EpiCept Corp. click here and for the rating history of EpiCept Corp. click here.
Shares of EpiCept Corp. closed at $0.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Taylor Devices (TAYD) Misses Q4 EPS by 31c
- Xylem names Andrea van der Berg as CFO, effective Sept. 2026
Create E-mail Alert Related Categories
New CoverageRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
